Prospective Natural History Study of Patients With Myotubular Myopathy and Other CentroNuclear Myopathies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-28

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is the 2 years extension of the prospective and longitudinal study of the natural history and functional status of patients with myotubular myopathy and other centronuclear (CNM) sponsored by Dynacure including ten additional pediatric patients with mutation in MTM1 or DNM2 genes). the patients are planned to be enrolled in one year leading to an expected total number of 70 patients followed at least over 1 year period. Data from the study will be used to characterize the disease course of CNM and determine which outcome measures will be the best to assess the efficacy of potential therapies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM)

NCT02057705

Myotubular Myopathy

COMPLETED

Natural History Study of Patients With Centronuclear Myopathies

NCT04977648

Centronuclear Myopathy

WITHDRAWN

Early Phase Human Drug Trial to Investigate DYN101 in Participants 2 to 17 Years With Centronuclear Myopathies

NCT04743557

Centronuclear Myopathy

WITHDRAWN PHASE1/PHASE2

The Natural History and Muscle Fatigability of Patients With Congenital Myopathies.

NCT06157268

Central Core Disease Multi-Minicore Disease Nemaline Myopathy +1 more

RECRUITING

Study of Genotype and Phenotype Characterization in Duchenne Muscular Dystrophy With Small Mutations

NCT05833633

Muscular Dystrophy, Duchenne

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Centronuclear Myopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standardized strength, respiratory and motor function assessments

Standardized assessments will be adjusted by the age, the ambulant status and the respiratory status of the patient. The visit frequency will also be adjusted according to the age and to the time spent in the study varying between quarterly to yearly.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of any age (newborns included) may participate
* Patients over 18 years of age and parent(s)/legal guardian(s) of patients \< 18 years of age must be provide written informed consent prior to participating in the study and informed assent will be obtained from minors at least 7 years of age when required by regulation.
* Myotubular Centronuclear myopathy (MTMCNM) resulting from a mutation in the MTM1, DNM2 or BIN1 gene
* Male or symptomatic female. A symptomatic female will be defined by the motor function assessment by Motor Function Measure (MFM) or North Star Ambulatory Assessment (NSAA) below 80% of the total score.
* Willing and able to comply with all protocol requirements and procedures.
* In France only: Affiliated to or a beneficiary of a social security category

Exclusion Criteria

* Other disease which may significantly interfere with the assessment of the MTM CNM and is clearly not related to the disease
* Currently enrolled in a treatment study; or treatment with an experimental therapy other than pyridostigmine
* For women: pregnancy or current breastfeeding

Eligible Sex

ALL

Accepts Healthy Volunteers

No